LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Listă Acțiuni・Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

Închisă

SectorSănătate

16.65 2.59

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

16.14

Maxim

16.88

Indicatori cheie
By Trading Economics
Venit	614M 331M
Vânzări	288M 731M
P/E Medie Sector	48.586 49.888
EPS	3.16
Marjă de profit	45.287
Angajați	835
EBITDA	628M 375M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	+36.45% upside

Dividende
By Dow Jones
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-531M 1.8B
Deschiderea anterioară	14.06
Închiderea anterioară	16.65

Sentimentul știrilor

By Acuity

50%

155 / 344 Clasament în Healthcare

Sarepta Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 iul. 2025, 15:04 UTC

Principalele dinamici ale pieței

Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments

21 iul. 2025, 11:31 UTC

Principalele dinamici ale pieței

Sarepta Stock Continues to Fall After Patient Death Linked to Investigational Gene Therapy

6 mai 2026, 22:50 UTC

Câștiguri

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

26 ian. 2026, 09:55 UTC

Acțiuni populare

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

4 nov. 2025, 14:39 UTC

Câștiguri

Acțiuni populare

Stocks to Watch Tuesday: Palantir, Sarepta, Tesla -- WSJ

4 nov. 2025, 12:45 UTC

Câștiguri

These Stocks Are Moving the Most Today: Palantir, Sarepta, Tesla, Uber, Pfizer, Norwegian Cruise Line, Amazon, AMD, and More -- Barrons.com

11 aug. 2025, 11:48 UTC

Câștiguri

These Stocks Are Moving the Most Today: C3.ai, Coinbase, Monday.com, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

11 aug. 2025, 11:11 UTC

Câștiguri

These Stocks Are Moving the Most Today: C3.ai, Coinbase, MicroStrategy, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

29 iul. 2025, 21:11 UTC

Câștiguri

These Stocks Moved the Most Today: SoFi, UnitedHealth, PayPal, Merck, Novo Nordisk, UPS, Sarepta, Boeing, Norfolk Southern, and More -- Barrons.com

29 iul. 2025, 12:14 UTC

Câștiguri

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, Novo Nordisk, UPS, Boeing, Sarepta, Whirlpool, and More -- Barrons.com

29 iul. 2025, 11:46 UTC

Câștiguri

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, UPS, Boeing, PayPal, Sarepta, Whirlpool, and More -- Barrons.com

21 iul. 2025, 12:53 UTC

Câștiguri

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, Pinterest, and More -- Barrons.com

21 iul. 2025, 11:17 UTC

Câștiguri

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, and More -- Barrons.com

21 iul. 2025, 10:25 UTC

Câștiguri

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Domino's, Cleveland-Cliffs, Verizon, and More -- Barrons.com

21 iul. 2025, 09:50 UTC

Câștiguri

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

21 iul. 2025, 09:12 UTC

Câștiguri

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

17 iul. 2025, 16:44 UTC

Câștiguri

These Stocks Are Moving the Most Today: Lucid, TSMC, Elevance, Sarepta, PepsiCo, Abbott Labs, Archer Daniels, and More -- Barrons.com

17 iul. 2025, 13:48 UTC

Câștiguri

These Stocks Are Moving the Most Today: Lucid, TSMC, United, Sarepta, PepsiCo, Abbott Labs, MP Materials, Archer Daniels, and More -- Barrons.com

17 iul. 2025, 10:57 UTC

Câștiguri

These Stocks Are Moving the Most Today: TSMC, United Airlines, Sarepta, PepsiCo, GE Aerospace, MP Materials, Archer Daniels, and More -- Barrons.com

17 iul. 2025, 09:08 UTC

Acțiuni populare

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

17 iun. 2025, 09:10 UTC

Acțiuni populare

Stocks to Watch Tuesday: SunRun, Enphase Energy, Mitsubishi, Roku -- WSJ

17 iun. 2025, 08:59 UTC

Acțiuni populare

Stocks to Watch Tuesday: Sunrun, Enphase Energy, Mitsubishi, Roku -- WSJ

16 iun. 2025, 08:55 UTC

Acțiuni populare

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

Comparație

Modificare preț

Sarepta Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

36.45% sus

Prognoză pe 12 luni

Medie 22.16 USD 36.45%

Maxim 38 USD

Minim 5 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSarepta Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

20 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 20 analiști care au acordat evaluări ale acțiunilor Sarepta Therapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

155 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.